https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gosh-researchers-receive-ucl-business-award/
GOSH researchers receive UCL Business Award
23 Jun 2017, 12:57 p.m.
Professors Bobby Gasper and Adrian Thrasher, both members of the BRC senior management team, have been awarded the UCL Business Award, in recognition of their work on the spin-out company Orchard Therapeutics.
Orchard is a biotechnology company focused on the development and commercialization of gene therapy medicines for children with rare diseases. It was launched in May 2016 with support from UCL Business and a £21 million investment from F-Prime Capital Partners.
Orchard focusses on restoring normal gene function in immunodeficiencies, metabolic diseases and haematological disorders and builds on GOSH researchers' expertise in stem, cell and gene therapies. Read more.
Professor Gaspar is Deputy Director of the NIHR GOSH BRC and Professor Thrasher is BRC Theme Lead for Gene, Stem and Cellular Therapies.
Teenager off to university after life-changing gene therapy
A teenager with a rare, life-limiting genetic condition is off to university after receiving a gene therapy that changed his life.
Stem cell treatment can improve rare skin condition in children
Children with a rare skin condition have found their symptoms have improved through taking part in the largest clinical trial of its kind, led by clinicians at Great Ormond Street Hospital for Children (GOSH).
Young people donate tissue samples to unlock mysteries of arthritis
A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.
Toddler doing well after receiving newest gene therapy available on NHS
A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.